1. Home
  2. PJT vs LQDA Comparison

PJT vs LQDA Comparison

Compare PJT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PJT Partners Inc.

PJT

PJT Partners Inc.

HOLD

Current Price

$152.17

Market Cap

3.5B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$45.19

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PJT
LQDA
Founded
2014
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.8B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
PJT
LQDA
Price
$152.17
$45.19
Analyst Decision
Hold
Buy
Analyst Count
7
8
Target Price
★ $161.11
$54.38
AVG Volume (30 Days)
409.1K
★ 5.3M
Earning Date
11-03-2026
11-10-2026
Dividend Yield
★ 0.67%
N/A
EPS Growth
N/A
★ 51.81
EPS
N/A
★ 1.26
Revenue
★ $1,713,671,000.00
$158,320,000.00
Revenue This Year
$8.41
$357.27
Revenue Next Year
$13.42
$1.34
P/E Ratio
★ $23.03
$36.28
Revenue Growth
14.77
★ 1031.18
52 Week Low
$127.73
$22.22
52 Week High
$195.62
$93.61

Technical Indicators

Market Signals
Indicator
PJT
LQDA
Relative Strength Index (RSI) 61.15 51.59
Support Level $144.58 $35.00
Resistance Level $163.37 $46.67
Average True Range (ATR) 4.42 2.99
MACD 2.60 2.79
Stochastic Oscillator 81.71 90.56

Price Performance

Historical Comparison
PJT
LQDA

About PJT PJT Partners Inc.

PJT Partners Inc is an advisory-focused investment bank that offers a portfolio of advisory services designed to help its clients achieve their strategic objectives. The company delivers a range of strategic advisory, capital markets advisory, restructuring and special situations, and shareholder advisory services to corporations, financial sponsors, institutional investors, and governments around the world. It also provides private fund advisory and fundraising services for alternative investment strategies, including private equity, real estate, hedge funds, and private credit. The company generates its revenue from advisory fees, placement services, and others. Geographically, it generates maximum revenue from the United States, followed by the United Kingdom and other markets.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: